NYHETER

2017 30 maj 17:30 Aktietorget
Peptonic Medical: Peptonic Medical files patent application for its vaginal gel

Stockholm May 30th, 2017. Peptonic Medical AB (publ) (‘Peptonic’ or the ‘Company’) today announced that the Company has filed a patent application concerning the use of its vaginal gel for the treatment of symptoms associated with vaginal atrophy. The application was filed with The Swedish Patent and Registration Office. During the coming twelve months, the Company needs to decide in which additional countries the application will be filed.

-          We have been working diligently with our patent attorneys to develop a patent application for the gel without oxytocin. Now we feel that we have found an innovative characteristic of the gel, which I’m very pleased about, says Johan Inborr, CEO of Peptonic Medical.

The Company has registered a new tradename - VagiVital® for the new product.

For more information, please contact:

Johan Inborr, CEO

Mobil: +46 708 853 893

E-post:  johan.inborr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 30th  May 2017. 

About Peptonic

Peptonic Medical AB (publ) is an innovative Swedish biopharma company developing products within the field of women’s health. The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free product for the treatment of vaginal atrophy.

VagiVital® is a registered trademark of Peptonic Medical. The product is being developed for the non-prescription use for the treatment of vaginal atrophy.

Find out more at www.peptonicmedical.se